Chicago, Illinois 60611


A phase I trial to evaluate the safety and tolerability of ALS-357 when administered for four weeks as a topical ointment, in escalating doses, to patients with cutaneous metastatic melanoma and to evaluate the effect of escalating doses of topically applied ALS-357 on histological remission of cutaneous metastatic melanoma and induction of apoptotic biomarkers.


Inclusion Criteria: - Study Participants must be 18 years or older. - Study Participants must have 2 sites of cutaneous metastatic melanoma that can not be removed with surgery. - Study Participants may have been previously treated with chemotherapy or immunotherapy but not with in 4 weeks of first dose of study treatment.



Primary Contact:

Principal Investigator
Timothy Kuzel, MD
Robert H. Lurie Cancer Center

Timothy Kuzel, MD
Phone: 312-695-1301

Backup Contact:


Location Contact:

Chicago, Illinois 60611
United States

Timothy Kuzel, MD
Phone: 312-695-1301

Site Status: Recruiting

Data Source:

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.